Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity.
about
Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspectsBiomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients.Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis.Toll-like receptor agonists: a patent review (2011 - 2013).Immunomodulatory oligonucleotides inhibit neutrophil migration by decreasing the surface expression of interleukin-8 and leukotriene B4 receptors.Nucleic acid-sensing TLRs and autoimmunity: novel insights from structural and cell biology.Type 1 Interferon in the Human Intestine-A Co-ordinator of the Immune Response to the Microbiota.Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease: A Meta-analysis.Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease.TLR Agonists as Adjuvants for Cancer Vaccines.Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.TLR9 regulates adipose tissue inflammation and obesity-related metabolic disorders.Emerging Mechanisms of Innate Immunity and Their Translational Potential in Inflammatory Bowel Disease.Emerging Therapies for Inflammatory Bowel Disease
P2860
Q27025290-9A51FA81-83DC-473E-BA9D-69EC18EF8834Q35155756-55488B5C-5BE8-49E2-A686-09D4BBF3ABD3Q37387994-BA89823D-7CF5-4D1A-A12C-674B23AE5409Q38181176-0D4CFBA2-683E-4CCA-8308-9577E70417D8Q38305188-FEDD1279-8C6F-4075-9ED1-1A1D6FCFE66EQ38673412-123CA31F-B407-472D-83BE-CCD1CBB3B68BQ38744710-7F47895B-D9F4-4C17-BCC2-21CFA24BB5C5Q38839998-BC6CC7A6-3283-4C7A-814D-80737CCE2A40Q39739400-1AB7619B-6F40-4DEC-9DC0-8BC69998E8B7Q41997055-BB2E1CD0-C229-4BFF-85C3-971124B4466BQ51544073-677EFFEA-57E2-4CE3-8541-B4B265E6DB26Q52925677-447C7976-5B0F-42D4-B779-0278693CBFEBQ55154729-D1AE25C7-898D-4F07-BA30-28ADCAF95384Q58099968-613272E0-C0D8-47C8-A884-97A6F1DBEA1A
P2860
Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Topical treatment with the Tol ...... ng glucocorticoid sensitivity.
@en
Topical treatment with the Tol ...... ng glucocorticoid sensitivity.
@nl
type
label
Topical treatment with the Tol ...... ng glucocorticoid sensitivity.
@en
Topical treatment with the Tol ...... ng glucocorticoid sensitivity.
@nl
prefLabel
Topical treatment with the Tol ...... ng glucocorticoid sensitivity.
@en
Topical treatment with the Tol ...... ng glucocorticoid sensitivity.
@nl
P2093
P2860
P356
P1476
Topical treatment with the Tol ...... ng glucocorticoid sensitivity.
@en
P2093
Arezou Zargari
Charlotte Admyre
Eugen Musch
Mouhamad Malek
Oliver D von Stein
Petra von Stein
Robert Löfberg
Tamim Lutfi
P2860
P304
P356
10.1002/IBD.23019
P577
2013-02-01T00:00:00Z